Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesHealius Ltd

Healius Ltd

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
0.5 AUD 0.01 ( 1.01%)
Last update at 2026-11-06T05:10:00Z
VOLUME
1024031
Market Cap
363.09M

Momentum Score

…

Healius Limited provides medical laboratory and pathology services in Australia. The company provides services under the Laverty Pathology, Dorevitch Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics Pathology, QML Pathology, TML Pathology, Abbott Pathology, IQ Pathology, Kossard, Gastrolab Dermatopathology, and Agilex Biolabs brands. It operates medical laboratories and patient collection centers. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in Sydney, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.48
Low
0.51
High
52 Week Price Range
0.30
Low
1.07
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Healius Ltd is an Australian healthcare company operating pathology, diagnostic imaging, day hospitals and primary care clinics. Long-term growth may be supported by an aging population, rising diagnostic and chronic-disease demand, and outsourcing trends that favor networked providers. Investors may find the company attractive for exposure to essential, recurring clinical services and opportunities to improve margins through integration and operational efficiencies.

Principal risks include exposure to government reimbursement and regulatory changes, competition and execution challenges in integrating services and managing workforce and cost pressures.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.49
Dividend Yield
-
Revenue TTM
1373.20M
Revenue Per Share
1.89
Gross Profit TTM
428.20M
Debt / Equity
5.82
ROE
-107.69%
Net Debt
931.50M
ROCE
3.01%
Diluted EPS TTM
-0.56

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -378.00M -592.10M -650.10M -397.30M 416.90M
Net income -415.60M -151.20M -645.80M -367.80M 307.90M
Selling general administrative - 35.80M 931.40M 864.30M 951.40M
Selling and marketing expenses - 24.40M 25.70M - -
Gross profit 254.00M 398.60M 1521.90M 1483.20M 2019.50M
Reconciled depreciation - 224.30M 281.20M 277.20M 278.50M
Ebit - 0.20M -579.30M 34.10M 432.40M
Ebitda 30.20M 31.20M -298.10M 311.30M 710.90M
Depreciation and amortization - 31.00M 281.20M 277.20M 278.50M
Operating income 30.20M 0.20M 65.50M 98.10M 484.40M
Other operating expenses 1343.00M 1005.80M 1680.70M 263.30M 775.30M
Interest expense 49.10M 65.10M 70.80M 28.60M 15.50M
Tax provision - -29.10M -14.10M -17.30M 122.90M
Interest income - 65.10M 70.80M 62.30M 50.50M
Net interest income - -65.10M -70.80M -62.30M -50.50M
Extraordinary items - 411.80M -9.80M 12.20M 13.90M
Income tax expense 30.90M 29.10M -14.10M -17.30M 122.90M
Total revenue 1373.20M 1344.20M 1746.20M 1706.90M 2336.20M
Total operating expenses 223.80M 60.20M 1456.40M 1385.10M 1531.60M
Cost of revenue 1119.20M 945.60M 224.30M 223.70M 316.70M
Total other income expense net -408.20M -592.30M -715.60M -433.10M -20.50M
Discontinued operations - - - 12.20M 13.90M
Net income from continuing ops - -563.00M -636.00M -380.00M 294.00M
Net income applicable to common shares - -151.20M -645.80M -367.80M 307.90M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 1417.60M 1777.00M 2982.80M 3653.20M 4136.80M
Intangible assets 61.00M 56.60M - 73.10M 75.20M
Other current assets 13.90M - 20.40M 31.60M 70.80M
Total liab 1246.10M 1189.10M 1942.10M 2147.00M 2215.20M
Total stockholder equity 171.50M 587.90M 1040.70M 1506.20M 1921.60M
Other current liab 91.20M - 128.10M 0.90M 5.70M
Common stock 2604.00M - 2603.90M 2421.00M 2422.90M
Capital stock - 2604.00M - 2421.00M 2422.90M
Retained earnings -2431.00M -2016.40M -1567.30M -923.30M -521.20M
Other liab - - - 14.40M 18.60M
Good will 98.00M 430.00M 1296.70M 1897.50M 2344.30M
Other assets - - - 87.90M 74.60M
Cash 67.20M 57.20M 60.10M 115.30M 81.30M
Total current liabilities 415.90M 446.20M 600.30M 629.60M 641.30M
Current deferred revenue - - 0.00M 147.70M 242.30M
Net debt 931.50M - 1537.80M 1650.70M 1697.70M
Short term debt 180.00M - 271.30M 263.00M 223.70M
Short long term debt total 998.70M - 1597.90M 1766.00M 1779.00M
Other stockholder equity -1.60M - -0.90M -1497.70M -1901.70M
Property plant equipment - - - 1243.30M 1270.90M
Total current assets 274.40M 251.90M 300.10M 344.30M 371.80M
Long term investments - - - 7.10M 5.80M
Net tangible assets - - - -464.40M -497.90M
Net receivables 158.30M 128.30M 187.70M 164.60M 219.70M
Long term debt - - - 562.10M 606.10M
Inventory 35.00M 29.80M 31.90M 32.80M 49.20M
Accounts payable 144.70M 133.90M 200.90M 218.00M 169.60M
Accumulated other comprehensive income 0.10M - 5.00M 8.50M 19.90M
Non currrent assets other 1.00M - 71.80M - -
Non current assets total 1143.20M 1525.10M 2682.70M 3308.90M 3765.00M
Capital lease obligations - 911.80M - 1203.90M 1172.90M
Long term debt total - - - 1503.00M 1555.30M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - 730.00M -63.00M 67.30M -401.70M
Change to liabilities - - - 44.80M -33.60M
Total cashflows from investing activities -65.20M 730.00M -63.00M 67.30M -401.70M
Net borrowings - -426.10M -142.50M -261.80M 131.10M
Total cash from financing activities -133.00M -1018.60M -259.00M -366.60M -176.50M
Change to operating activities - - - -31.60M 2.50M
Net income -408.90M -151.20M -636.00M -367.80M 307.90M
Change in cash 10.00M -2.90M -55.20M 34.00M 8.60M
Begin period cash flow 57.20M 60.10M 115.30M 81.30M 72.70M
End period cash flow 67.20M 57.20M 60.10M 115.30M 81.30M
Total cash from operating activities 208.20M 285.70M 266.80M 333.30M 586.80M
Issuance of capital stock - - 179.30M - -
Depreciation - 238.80M 281.20M 262.60M 265.00M
Other cashflows from investing activities - 784.80M -11.00M 143.40M -308.20M
Dividends paid - -299.90M - 34.30M 98.10M
Change to inventory -5.20M -0.90M 0.90M 14.50M -12.40M
Change to account receivables -6.60M 14.90M -21.20M 52.60M -33.00M
Sale purchase of stock - 0.00M 179.30M -8.90M -139.40M
Other cashflows from financing activities -233.00M -73.10M -295.80M -278.40M 61.00M
Change to netincome - - - 431.80M 40.30M
Capital expenditures 43.30M 54.00M 64.00M 76.10M 93.50M
Change in working capital 9.30M 17.00M -38.70M 67.10M -45.40M
Stock based compensation - 0.10M 0.40M -7.80M 7.90M
Other non cash items 607.80M 181.00M 660.30M 438.50M 13.90M
Free cash flow 164.90M 231.70M 173.80M 257.20M 493.30M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
HLS
Healius Ltd		 0.01
1.01%		 0.50 - 29.24 0.26 2.08 0.94 10.14
SHL
Sonic Healthcare Ltd		 0.18
0.91%		 20.06 16.16 17.21 0.90 1.15 1.36 8.10
IDX
Integral Diagnostics Ltd		 0.01
0.58%		 1.74 28.83 15.24 0.82 0.97 1.52 9.49
ACL
Australian Clinical Labs Ltd		 0.04
1.25%		 3.24 26.67 16.84 0.81 3.95 1.24 5.12
MVF
Monash Ivf Group Ltd		 -
-%		 0.74 37.00 16.21 1.07 1.17 1.79 11.73

Profile*

Healius Ltd

Healius Limited provides medical laboratory and pathology services in Australia. The company provides services under the Laverty Pathology, Dorevitch Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics Pathology, QML Pathology, TML Pathology, Abbott Pathology, IQ Pathology, Kossard, Gastrolab Dermatopathology, and Agilex Biolabs brands. It operates medical laboratories and patient collection centers. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in Sydney, Australia.

161 Castlereagh Street, Sydney, NSW, Australia, 2000

61 2 9432 9400

https://www.healius.com.au

3343

Name Title Year Born
Dr. Malcolm W. Parmenter B.S., M.A.I.C.D., M.S. MD, CEO & Director 1955
Ms. Maxine Jaquet CFO & COO NA
Mr. John McKechnie Chief Exec. of the Pathology Division NA
Mr. Rob Phipps Group Exec. of People & Culture and Sustainability NA
Mr. Henry Barclay Chief Exec. of Day Hospitals NA
Mr. Charles Tilley B.Sc., FCIS, L.L.B., B.Sc. (Hons), LLB (Hons) Company Sec. NA
Ms. Alison Stephenson Additional Company Sec. NA
Ms. Janet Payne Group Exec. of Corp. Affairs NA
Dr. John Houston Advisor NA
Ms. Maxine Jaquet B.Com. MD, CEO & Director NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…